Treats relapsed or refractory diffuse large B-cell lymphoma (DLBCL) … low grade lymphoma. Sold as Monjuvi. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Tafasitamab-Cxix (sold as Monjuvi), first approved Jul 31, 2020, with 1 new use approved and 0 published complete response letters.
| Monjuvi | Part B | $46.2M | +7% | 542 |
| Monjuvi | Part D | $1.7M | +66% | 20 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaClassic Follicular Lymphoma, Grade 1 Follicular Lymphoma · University of Washington | Phase 2 | Recruiting | Jul 28, 2026 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · City of Hope Medical Center | Phase 2 | Recruiting | May 12, 2026 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersAutoimmune Disorders, Systemic Sclerosis · M.D. Anderson Cancer Center | Phase 1 / Phase 2 | Recruiting | May 30, 2024 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaChronic Lymphocytic Leukemia · OHSU Knight Cancer Institute | Phase 1 | Recruiting | Jul 13, 2023 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · Academic and Community Cancer Research United | Phase 2 | Recruiting | Jun 20, 2023 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentGrade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma · SWOG Cancer Research Network | Phase 2 | Recruiting | Jun 6, 2023 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · David Bond, MD | Phase 2 | Active, not recruiting | Apr 20, 2023 |
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderMonomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder · Timothy Voorhees | Phase 2 | Recruiting | Mar 27, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 31, 2020 | MonjuviBLA 761163 · New molecular entity | Morphosys US Inc | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA